Everence Capital Management Inc. Invests $593,000 in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Everence Capital Management Inc. purchased a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 2,520 shares of the biopharmaceutical company’s stock, valued at approximately $593,000.

Several other large investors have also recently added to or reduced their stakes in the company. Eventide Asset Management LLC raised its stake in shares of Alnylam Pharmaceuticals by 157.9% during the 3rd quarter. Eventide Asset Management LLC now owns 224,333 shares of the biopharmaceutical company’s stock worth $61,698,000 after buying an additional 137,333 shares in the last quarter. Los Angeles Capital Management LLC grew its holdings in Alnylam Pharmaceuticals by 11,433.4% during the third quarter. Los Angeles Capital Management LLC now owns 137,017 shares of the biopharmaceutical company’s stock worth $37,684,000 after acquiring an additional 135,829 shares during the period. AQR Capital Management LLC raised its position in Alnylam Pharmaceuticals by 92.5% in the second quarter. AQR Capital Management LLC now owns 271,619 shares of the biopharmaceutical company’s stock worth $65,862,000 after acquiring an additional 130,482 shares in the last quarter. Deerfield Management Company L.P. Series C acquired a new stake in Alnylam Pharmaceuticals in the second quarter valued at $29,111,000. Finally, Avoro Capital Advisors LLC boosted its position in shares of Alnylam Pharmaceuticals by 33.3% during the 2nd quarter. Avoro Capital Advisors LLC now owns 400,000 shares of the biopharmaceutical company’s stock worth $97,200,000 after purchasing an additional 100,000 shares in the last quarter. 92.97% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, CMO Pushkal Garg sold 1,682 shares of the company’s stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $422,148.36. Following the completion of the sale, the chief marketing officer now directly owns 17,457 shares of the company’s stock, valued at approximately $4,381,357.86. This represents a 8.79 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Tolga Tanguler sold 1,469 shares of the firm’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total value of $368,689.62. Following the completion of the transaction, the executive vice president now directly owns 13,191 shares in the company, valued at $3,310,677.18. This trade represents a 10.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 10,122 shares of company stock valued at $2,540,455 over the last ninety days. Corporate insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Trading Up 0.3 %

Shares of ALNY opened at $234.28 on Friday. Alnylam Pharmaceuticals, Inc. has a twelve month low of $141.98 and a twelve month high of $304.39. The firm has a market capitalization of $30.22 billion, a P/E ratio of -89.42 and a beta of 0.34. The company has a current ratio of 2.75, a quick ratio of 2.69 and a debt-to-equity ratio of 31.64. The stock’s fifty day simple moving average is $252.99 and its 200 day simple moving average is $257.91.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The firm had revenue of $500.90 million during the quarter, compared to analyst estimates of $532.91 million. Alnylam Pharmaceuticals’s quarterly revenue was down 33.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.15 earnings per share. On average, equities research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -2.21 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the stock. StockNews.com upgraded shares of Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, December 27th. Raymond James lifted their price target on shares of Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the company an “outperform” rating in a research report on Friday, November 1st. Wolfe Research lowered Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a research note on Tuesday, November 12th. William Blair reaffirmed an “outperform” rating on shares of Alnylam Pharmaceuticals in a report on Tuesday, November 19th. Finally, Scotiabank upped their target price on Alnylam Pharmaceuticals from $305.00 to $310.00 and gave the company a “sector outperform” rating in a report on Friday, November 1st. One analyst has rated the stock with a sell rating, five have given a hold rating and nineteen have assigned a buy rating to the stock. According to data from MarketBeat.com, Alnylam Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $298.09.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.